
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health has demonstrated a robust financial trajectory, achieving a 7% year-over-year growth in a challenging competitive environment, primarily through enhancing its data offerings and new partnerships. The company is poised for significant upside driven by the growth of Guardant Reveal in the cancer recurrence monitoring market and the Shield colorectal cancer screening franchise, alongside improvements in reimbursement and guideline inclusions. Guardant Health maintains over 50% market share in its primary segment and is expected to see expanding average selling prices (ASP) and increased test volume, particularly with recent advancements in reimbursement and pricing strategies.
Bears say
Guardant Health's stock outlook is negatively impacted by the high price-to-earnings (P/E) multiple currently valued in the upper half of its multi-year average, which may not be sustainable due to external factors. The company faces significant risks related to reimbursement dynamics that could diminish average selling prices (ASP) and lead to a potential revenue reduction of approximately $100 million if PAMA regulations are implemented. Additionally, uncertainties surrounding the regulatory landscape for multi-cancer early detection (MCED) tests pose challenges that could hinder revenue growth and adoption of Guardant's assays, further straining profitability and future financial performance.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares